Travere Therapeutics
Logotype for Travere Therapeutics Inc

Travere Therapeutics (TVTX) investor relations material

Travere Therapeutics Study update summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Travere Therapeutics Inc
Study update summary13 Apr, 2026

FDA approval and clinical significance

  • FILSPARI (sparsentan) received FDA approval to reduce proteinuria in adults and pediatric patients aged eight and older with FSGS without nephrotic syndrome, becoming the first and only approved therapy for this condition.

  • Approval is based on phase III DUPLEX study data, showing significant reductions in proteinuria, improved eGFR, and kidney outcomes in the defined patient population.

  • FILSPARI demonstrated a 48% reduction in proteinuria versus 27% for irbesartan at week 108, and a 29% greater reduction in UPCR from baseline (p=0.0075), with favorable eGFR outcomes and lower progression to kidney failure (RR: 0.19, p=0.018).

  • FILSPARI achieved more than three times higher complete remission rates at key proteinuria thresholds versus irbesartan.

  • The safety profile was comparable to irbesartan and consistent across clinical subgroups, with common adverse reactions including peripheral edema, hypotension, hyperkalemia, dizziness, anemia, and transaminase elevations; liver monitoring is required.

Patient population and clinical practice

  • FSGS is a rare, severe, and progressive kidney disease with the lowest 7-year kidney survival rate among primary glomerular diseases, often leading to kidney failure and high unmet need.

  • Less than 20% of FSGS patients have active nephrotic syndrome at a single point in time; the condition is relapsing and remitting.

  • Over 4,000 people in the U.S. are on the kidney transplant waitlist due to FSGS, and up to 55% of transplant patients experience disease recurrence.

  • Median time to kidney failure is 5–10 years for 30–60% of patients.

  • The addressable US patient population for FILSPARI now exceeds 30,000 FSGS patients, with the total addressable population over 100,000 including IgAN.

Commercial strategy and market opportunity

  • FILSPARI's launch in FSGS builds on its established presence in IgA nephropathy, leveraging existing commercial infrastructure and physician relationships, with over 100 field professionals and expanded sales coverage to 7,000 nephrologists.

  • Over 80% of nephrologists view FSGS as a high unmet need and are familiar with FILSPARI, which is the most desired product candidate among specialists.

  • FILSPARI is already included in many payer formularies for IgA nephropathy, supporting rapid access for FSGS patients.

  • The estimated U.S. peak opportunity for FILSPARI exceeds $3 billion, with growth expected from expanding indications and increased patient identification.

  • No significant bolus of patients is expected at launch; uptake will follow regular nephrology visit cadence.

Impact of IgAN prescriber overlap on FSGS launch
eGFR slope in FSGS without nephrotic syndrome
Drivers for expanding the addressable FSGS market
Market size impact of nephrotic syndrome exclusion
FSGS pricing dynamics vs IgAN indication
Patient transition from nephrotic to eligible
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Travere Therapeutics earnings date

Logotype for Travere Therapeutics Inc
Q1 20264 May, 2026
Travere Therapeutics
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Travere Therapeutics earnings date

Logotype for Travere Therapeutics Inc
Q1 20264 May, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Explore our global coverage